Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 230 Squamous Cell Carcinoma of Head and Neck 139 Head and Neck Neoplasms 131 Lung Neoplasms 117 Esophageal Neoplasms 88 Stomach Neoplasms 84 Uterine Cervical Neoplasms 68 Esophageal Squamous Cell Carcinoma 66 Urinary Bladder Neoplasms 59 Breast Neoplasms 55 Nasopharyngeal Carcinoma 51 Small Cell Lung Carcinoma 46 Carcinoma, Squamous Cell 39 Neoplasm Metastasis 38 Pancreatic Neoplasms 36 Neoplasms 35 Biliary Tract Neoplasms 34 Oropharyngeal Neoplasms 32 Cholangiocarcinoma 32 Ovarian Neoplasms 30 Mesothelioma, Malignant 28 Adenocarcinoma Of Esophagus 28 Lymphoma 25 Carcinoma 24 Adenocarcinoma of Lung 24 Central Nervous System Neoplasms 22 Laryngeal Neoplasms 20 Carcinoma, Ovarian Epithelial 20 Recurrence 19 Lymphoma, Large B-Cell, Diffuse 19

Interventions

enfortumab vedotin 2 Gemcitabine 2 Carboplatin 2 zimberelimab 1 sacituzumab govitecan 1 pembrolizumab 1 olaparib 1 avelumab 1 Oxaliplatin 1 Nivolumab 1 Cisplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Metastatic Urothelial Cancer × Cisplatin × Clear all

NCT03547973 2026-03-16

TROPHY U-01

Gilead Sciences

Phase 2 Recruiting

827 enrolled 1 FDA

Metastatic Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡